Our recent paper (26) showed that mucosal delivery of BcfA-adjuvanted acellular pertussis vaccines elicited CD4+IL-17+ tissue-resident memory T cells (TRM) in the nose and reduced nasal bacterial burden. This evidence concerns the gene IL17A and pertussis.